Update: Lithium-ion Battery Expert Martin Kepman Reports on the Lithium-ion Battery Market

Written by Customer Service on April 9, 2022. Posted in Public Companies.

Martin Kepman, a Canadian lithium-ion battery futurist and CEO of Manganese X Energy recently released a report on the future of the lithium-ion battery market. Saint-Laurent , April 09, 2022 (GLOBE NEWSWIRE) — Lithium-ion battery expert Martin Kepman forecasts that in the next few years, there will be a large demand for a Canadian and U.S. rare mineral supply chain. This is especially true for manganese, which is an important mineral for electric vehicles powered by lithium-ion batteries and energy storage devices. The current electric car and EV revolution has shown manganese to be an essential mineral in all future lithium-ion batteries, with the potential to produce more power, have more stability, with larger capacities, and be safer for consumers. The full report is available here and is available for download. Source...

Islandsbanki hf.: Major Shareholder Announcement – Lífeyrissjóður starfsmanna ríkisins

Written by Customer Service on April 9, 2022. Posted in Public Companies.

Enclosed is a major shareholder announcment from Lífeyrissjóður starfsmanna ríkisins. Contacts Investor Relations – Margrét Lilja Hrafnkelsdóttir, ir@islandsbanki.is and tel: +354 844 4033 Public Relations – Edda Hermannsdóttir, pr@islandsbanki.is and tel: +354 844 4005 Attachment floggun_LSR_april

Conciliator interrupts the conciliation between UPM Communication Papers and Paperworkers’ Union, conciliation continues in other UPM businesses

Written by Customer Service on April 9, 2022. Posted in Public Companies.

(UPM, Helsinki, 9 April 2022 at 11:30 EEST) – The conciliator has announced that the conciliation between UPM Communication Papers and Paperworkers’ Union has been interrupted, as the parties’ views are still far apart. At the same time, the conciliator announced that the conciliation in UPM Specialty Papers, UPM Raflatac and UPM Biofuels continues. For UPM Pulp the conciliator has already submitted a settlement proposal. Unlike before, the Paperworkers’ Union is now ready to finalise agreements for UPM’s different businesses non-simultaneously. This means that UPM Specialty Papers, UPM Raflatac, and UPM Biofuels prepare to find solutions on the same schedule as UPM Pulp, which is expected to state its position on the settlement proposal by April 14, 2022. Next meetings between UPM Communication Papers and the Paperworkers’ Union have...

Martin Kepman Futurist and CEO of Manganese X Energy Reports on the Lithium-ion Battery Market.

Written by Customer Service on April 9, 2022. Posted in Public Companies.

Martin Kepman, a Canadian lithium-ion battery futurist and CEO of Manganese X Energy recently released a report on the future of the lithium-ion battery market. Saint-Laurent , April 09, 2022 (GLOBE NEWSWIRE) — Lithium-ion battery expert Martin Kepman forecasts that in the next few years, there will be a large demand for a Canadian and U.S. rare mineral supply chain. This is especially true for manganese, which is an important mineral for electric vehicles powered by lithium-ion batteries and energy storage devices. The current electric car and EV revolution has shown manganese to be an essential mineral in all future lithium-ion batteries, with the potential to produce more power, have more stability, with larger capacities, and be safer for consumers. Source https://evadoption.com/ev-sales/ev-sales-forecasts/ Martin recently...

AnPac Bio Appoints Dr. Aidong Chen as New Chief Executive Officer and Chairman of the Board and Miss Sheng Liu as a New Board Member

Written by Customer Service on April 9, 2022. Posted in Public Companies.

PHILADELPHIA, April 08, 2022 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that Dr. Aidong Chen has joined the Company as its board director, Chief Executive Officer and Chairman of the Board of Directors. Dr. Aidong Chen has been a practicing physician and researcher for over 10 years. He has received over 20 global patents on his work and published 91 papers over his career. Dr. Chen has been affiliated with many leading hospitals, including Yijishan Hospital, and Nanjing Medical University. He has replaced Dr. Chris Yu, Company’s founder, who resigned as board director, CEO and Chairman of the Board of the Company. As head of China operations of...

Junshi Biosciences and Coherus Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting

Written by Customer Service on April 9, 2022. Posted in Public Companies.

– Toripalimab plus chemotherapy provided superior progression free survival, overall survival, overall response rate and duration of response compared to chemotherapy alone – SHANGHAI, China, and REDWOOD CITY, Calif., April 09, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) announced the results of the prespecified final progression-free survival (“PFS”) analysis and the interim overall survival (“OS”) analysis of the JUPITER-02 study (NCT03581786), a pivotal Phase 3 trial in first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (“NPC”). The JUPITER-02 results are summarized in a poster presentation at the annual meeting of the American Association for Cancer Research (“AACR”). In the final PFS...

FluroTech Provides Operational Update: Announces Pause on Further Development of its Pandemic and Emerging Disease Defense Platform

Written by Customer Service on April 9, 2022. Posted in Public Companies.

CALGARY, Alberta, April 08, 2022 (GLOBE NEWSWIRE) — FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (the “Company” or “FluroTech”), announces that it has decided to pause any further expenditures on development of its Pandemic and Emerging Disease Defense Platform (“PEDDP”), initially targeting COVID-19, until it is able to obtain further financing. While management continues to believe that its COVID-19 testing technology will be viable and needed, the Company will require additional financing to complete the technology through to regulatory approvals in order to become commercial. To that end, management continues to pursue financing options. Readers are cautioned that, although the Company has achieved proof of concept prototype, the testing method and device is still in the pre-approval stage and accordingly the Company is not currently...

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30

Day: April 9, 2022